CHARLOTTE – Monarch Medical Technologies, which specializes in precision insulin dosing technology, has appointed Bruce Lisanti as its new president and chief executive officer.
He replaces Linda Beneze, who retired from the role earlier this year.
“With his extensive experience leading high-growth healthcare technology companies, Bruce is well-equipped to take the helm of Monarch and drive the continued advancement of the EndoTool® Glucose Management System to help providers improve their clinical and financial outcomes through effective glycemic management,” said Christophe Mallard, managing member of private investment firm Eigen Capital Holdings LLC, which owns Monarch Medical Technologies, in a statement.
Monarch Medicals new president and CEO Bruce Lisanti. SOURCE: LinkedIn.
Lisanti has more than 25 years experience working as a senior executive in healthcare, technology and services industries. He perviously worked for General Electric Company (GE), where he reportedly helped grow a new division from a startup to over $1.2B in revenue. He has also worked with high growth companies, helping build several from start-ups to over $500 million in revenue.
“I’m very excited to be joining Monarch at this moment in the healthcare industry and work with this phenomenal team to advance inpatient diabetes care,” said Lisanti in a statement.
“As more hospitals face financial pressures under value-based care payment models and increased competition with the rise of healthcare consumerism, the need to improve inpatient diabetes care is no longer just what is in the best interest of the patient, but also the provider’s bottom-line. EndoTool is well positioned as a proven solution to enhance the safety of insulin dosing, improve patient outcomes, and reduce the cost of care, benefiting both patients and providers.”
